Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKTXNASDAQ:CLSNNASDAQ:FCSCNASDAQ:JAGXNASDAQ:MBRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.80-4.3%$2.30$1.66▼$5.50$10.17M1.0210,482 shs34,767 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsFCSCFibrocell Science$3.00$3.00$1.45▼$3.28$29.28M1.6778,673 shsN/AJAGXJaguar Health$0.07$0.08$0.05▼$1.22$3.70M1.3138.50 million shs29.80 million shsMBRXMoleculin Biotech$5.54+18.4%$7.88$4.34▼$24.75$12.35M1.9830,477 shs89,236 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-3.23%-5.25%-19.64%-40.00%-52.43%CLSNImunon0.00%0.00%0.00%0.00%0.00%FCSCFibrocell Science0.00%0.00%0.00%0.00%0.00%JAGXJaguar Health+5.65%-8.76%+21.50%-54.97%-90.65%MBRXMoleculin Biotech+18.38%-12.19%-37.29%-50.76%-61.11%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech3.1012 of 5 stars3.55.00.00.03.00.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari TherapeuticsN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$101.671,735.14% UpsideCurrent Analyst RatingsLatest FCSC, MBRX, AKTX, CLSN, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.48 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00FCSCFibrocell Science$350K83.66N/AN/A$0.98 per share3.06JAGXJaguar Health$11.96M0.31N/AN/A($0.32) per share-0.23MBRXMoleculin BiotechN/AN/AN/AN/A$27.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.75MN/A0.00∞N/AN/AN/AN/A5/6/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AFCSCFibrocell Science-$10.28M-$1.45N/AN/AN/AN/A23.10%10.56%N/AJAGXJaguar Health-$47.45MN/A0.00N/AN/A-370.40%-1,191.67%-79.95%N/AMBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AFCSCFibrocell ScienceN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A1.56N/ACLSNImunon0.136.526.52FCSCFibrocell Science0.475.095.09JAGXJaguar Health22.001.771.10MBRXMoleculin BiotechN/A3.867.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%CLSNImunon12.97%FCSCFibrocell Science36.72%JAGXJaguar Health12.04%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics61.80%CLSNImunon4.66%FCSCFibrocell Science1.10%JAGXJaguar Health0.16%MBRXMoleculin Biotech6.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics155.65 million2.16 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableFCSCFibrocell Science199.76 millionN/AOptionableJAGXJaguar Health6050.76 million50.68 millionNo DataMBRXMoleculin Biotech152.23 million2.08 millionNot OptionableFCSC, MBRX, AKTX, CLSN, and JAGX HeadlinesSourceHeadlineMoleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - March 28 at 3:34 AMEquities Analysts Set Expectations for Moleculin Biotech, Inc.'s FY2028 Earnings (NASDAQ:MBRX)americanbankingnews.com - March 28 at 1:36 AMMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLfinance.yahoo.com - March 27 at 1:35 PMMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunityprnewswire.com - March 27 at 9:25 AMMoleculin Biotech (NASDAQ:MBRX) Price Target Lowered to $20.00 at Maxim Groupamericanbankingnews.com - March 27 at 3:18 AMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 26 at 9:48 AMNews - Moleculin Biotechthepharmaletter.com - March 25 at 11:47 PMMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinanznachrichten.de - March 25 at 6:45 PMMoleculin skyrockets on interim data for annamycin MB-106 trialthepharmaletter.com - March 25 at 6:45 PMMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLmarkets.businessinsider.com - March 25 at 9:05 AMMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinance.yahoo.com - March 25 at 9:05 AMMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial Resultsfinanznachrichten.de - March 23 at 10:20 AMMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023investorplace.com - March 22 at 10:03 PMMoleculin Biotech Inc Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:18 PMMoleculin Reports Full Year 2023 Financial Resultsprnewswire.com - March 22 at 4:05 PMMoleculin Biotech announces 1-for-15 reverse stock splitinvesting.com - March 21 at 11:00 PMA Preview Of Moleculin Biotech's Earningsbenzinga.com - March 21 at 5:59 PMMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock Splitfinanznachrichten.de - March 20 at 1:07 PMMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcastprnewswire.com - March 20 at 7:30 AMMoleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.comamericanbankingnews.com - March 20 at 3:30 AMMoleculin Announces Reverse Stock Splitfinance.yahoo.com - March 19 at 9:29 PMMoleculin to Present at the 36th Annual ROTH Conferencefinance.yahoo.com - March 12 at 9:24 AMA new chapter for biotech: Confidence returns to the marketfiercebiotech.com - March 5 at 8:18 AMHere's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situationfinance.yahoo.com - February 6 at 3:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkari TherapeuticsNASDAQ:AKTXAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Fibrocell ScienceNASDAQ:FCSCFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.